Treatment
GLP-1 clinical trials
We’re tracking 88 recruiting studies that include GLP-1, each written for real people, not researchers, below.
Recruiting studies
- NCT06654219Recruiting
Clear liquids before endoscopy for patients on GLP-1 meds
This study tests whether drinking only clear liquids before an upper endoscopy can reduce leftover stomach contents in people taking GLP-1 medications (like Ozempic or Mounjaro). It may help make the procedure safer.
Houston, TexasAges 18 years+ - NCT07736963Recruiting
Stopping GLP-1 drugs before colonoscopy: a trial in Taiwan
This study looks at whether stopping GLP-1 receptor agonists (a type of diabetes or weight-loss medication) before a colonoscopy can help improve the procedure. It compares how well the bowel is cleaned in people who stop these drugs for a certain time versus those who continue them.
New Taipei, TaiwanAges 18–90 - NCT07736911RecruitingPhase 3
Should you pause your diabetes medication before a stomach scope?
This trial is testing whether stopping GLP-1 receptor agonists or tirzepatide one week before an upper endoscopy (a scope that looks at your stomach and esophagus) is safe and effective. It's designed for people who are already taking these medications and have an upcoming procedure.
New Taipei City, TaiwanAges 18–90 - NCT07042672Recruiting
Therapy and medication for binge eating in obesity
This trial tests whether a medication (liraglutide) plus behavioral counseling helps people with severe obesity and binge-eating disorder reduce binge episodes, lose weight, and improve coping. Participants will receive either liraglutide or placebo, along with group therapy sessions.
Bergen, VestlandAges 18–65 - NCT07082062Recruiting
GLP-1 formula for glucose control
This trial tests whether a special GLP-1 formula can help regulate blood sugar and increase GLP-1 levels in people with higher body fat. It may offer a new way to support metabolic health.
TaichungAges 18–50 - NCT07640139Enrolling by invitation
Study of Weight-Loss Medications' Health and Cost Effects
This research study looks at how obesity medications affect people's health outcomes and healthcare costs. Researchers will track employees and their family members covered by participating Indiana employers to understand whether these medications help improve conditions like diabetes and heart health.
Indianapolis, IndianaAges 18–64 - NCT07207148Recruiting
Ocrelizumab and weight-loss drugs for MS
This study looks at combining ocrelizumab (an MS treatment) with GLP-1 agonists (like Ozempic, used for weight management) in people with MS. It aims to see if the combination is safe and beneficial.
Chicago, IllinoisAges 18–70 - NCT07572513Recruiting
How special carbohydrates affect hormone release in healthy adults
This study tests whether eating carbohydrates that digest slowly can naturally boost a hormone called GLP-1, which helps control blood sugar and appetite. Researchers want to understand if this might help people manage their weight and metabolism.
West Lafayette, IndianaAges 18–45 - NCT07111494RecruitingPhase 4
GLP-1 medication for psoriatic arthritis outcomes
This study tests if adding a GLP-1 medication (a type of drug that helps with weight and blood sugar) to your usual psoriatic arthritis treatment can improve your joint and skin symptoms. It is for people with psoriatic arthritis who have not yet achieved good control of their disease and have a higher body weight.
Milwaukee, WisconsinAges 18 years+ - NCT07169136Recruiting
GLP-1 medicine for PCOS in teens with obesity
This trial tests if a medicine called a GLP-1 agonist (like semaglutide) can help with hormone and ovulation problems in adolescent girls with PCOS and obesity. It aims to improve irregular periods and other PCOS symptoms.
Jacksonville, FloridaAges 12–18 - NCT06976619RecruitingPhase 2
Blood sugar control and a diabetes drug on insulin production
This study looks at how blood sugar control and a class of drugs called GLP-1 agonists (like Ozempic) affect insulin-making cells in people with type 1 or type 2 diabetes who use insulin.
Rochester, MinnesotaAges 25–70 - NCT07092618RecruitingPhase 2/Phase 3
Trial for keeping weight off after stopping GLP-1 meds
This study tests if other medicines (naltrexone, metformin, or rapamycin) can help people keep off weight they lost while taking GLP-1 drugs like Wegovy or Ozempic, after they stop taking them. It is for AgelessRx patients aged 40 to 85 who have lost at least 15 pounds on GLP-1s.
Chicago, IllinoisAges 40–85 - NCT06843512Recruiting
How GLP-1 meds change eating habits
This study looks at how starting a GLP-1 medication (like Wegovy or Ozempic) changes your food choices and eating habits. It may help you understand if these medicines work for weight loss.
State College, PennsylvaniaAges 18 years+ - NCT07398300Recruiting
How GIP and GLP-1 affect insulin and blood flow in the body
This study uses a special full-body PET scan to see how two natural hormones, GIP and GLP-1, affect how your body uses sugar and moves blood. It includes healthy volunteers and people with type 2 diabetes who are on metformin only.
CopenhagenAges 23–64 - NCT06903923RecruitingPhase 2
Bone health in teens and young adults taking GLP-1 weight loss drugs
This trial looks at how GLP-1 receptor agonist medications (like liraglutide or semaglutide) affect bone health in adolescents and young adults with obesity. It aims to understand if these weight loss drugs have any impact on bone density and metabolism.
Charlottesville, VirginiaAges 12–21 - NCT06581120Enrolling by invitation
Stomach ultrasound study for diabetes and obesity
This study uses ultrasound to see how GLP-1 RA medications (like Ozempic) affect the stomach in people with type 2 diabetes and obesity. It may help doctors better understand how these medicines work.
Cincinnati, OhioAges 10–25 - NCT07437911Recruiting
Can a Supplement Help with Nutrient Gaps for GLP-1 Users?
This study tests whether a daily supplement can help fill nutrient gaps and improve gut health for people who are already taking GLP-1 weight-loss medications (like Ozempic or Wegovy). Participants must be on a stable dose for at least 8 weeks and be generally healthy without other chronic conditions.
Santa Monica, CaliforniaAges 18–59 - NCT07720414Recruiting
GLP-1 Meds and Breastfeeding Study
This study tests whether a type of diabetes/weight loss medication (GLP-1 RA, given as a shot) affects milk production in breastfeeding mothers. It may help women who need this medicine while nursing.
Aurora, ColoradoAges Any age - NCT07012642RecruitingEarly Phase 1
GLP-1 drugs for arm or leg swelling (lymphedema)
This trial tests if a class of diabetes drugs (GLP-1 receptor agonists) can reduce swelling in one arm or leg caused by lymphedema. It may help people who have not found relief from other treatments.
Red Bank, New JerseyAges 18 years+ - NCT07616037RecruitingPhase 2
New hormone treatment for polycystic ovary syndrome
This study tests a new medication that combines two hormone-like drugs to treat polycystic ovary syndrome (PCOS), a condition affecting ovulation and hormone balance. The trial aims to see if this dual-action drug can improve irregular periods and other PCOS symptoms better than current treatments.
Shanghai, Shanghai MunicipalityAges 18–40 - NCT05356104RecruitingPhase 2
GLP-1 treatment to slow small blood-vessel brain damage
This Phase 2 study tests whether a GLP-1–like medicine can slow worsening “small vessel” disease changes in the brain and related walking and thinking problems. It aims to see if the treatment can prevent progression in people who already show early brain changes on MRI.
Wenzhou, ZhejiangAges 55–80 - NCT06132477RecruitingPhase 4
Study of GLP-1 medicines after weight loss surgery
This study looks at what happens when people taking a GLP-1 medication (like Ozempic) either stop or continue it after weight loss surgery. The goal is to learn whether staying on the medicine helps with long-term weight control.
Columbia, MissouriAges 18 years+ - NCT06924697Enrolling by invitation
Testing a diabetes drug to help men quit smoking
This study tests if a medication used for type 2 diabetes (GLP-1 receptor agonists) can also reduce smoking in men with diabetes who smoke. If you qualify, you may receive this drug or a standard diabetes pill to see if it helps you smoke less.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07605572Recruiting
GLP-1 drugs and dry eye disease in type 2 diabetes
This study tests whether a diabetes and weight-loss medication called GLP-1 receptor agonists affects dry eye disease. Researchers want to see if this medication helps or worsens dry eyes in people with type 2 diabetes and obesity.
AthensAges 18 years+
What GLP-1 is being studied for
Conditions with recruiting GLP-1 studies.
Common questions
- Are there clinical trials studying GLP-1?
- Yes. Clin2 currently lists 88 recruiting studies that include GLP-1, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a GLP-1 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is GLP-1 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether GLP-1 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.